JP2010501478A5 - - Google Patents

Download PDF

Info

Publication number
JP2010501478A5
JP2010501478A5 JP2009523852A JP2009523852A JP2010501478A5 JP 2010501478 A5 JP2010501478 A5 JP 2010501478A5 JP 2009523852 A JP2009523852 A JP 2009523852A JP 2009523852 A JP2009523852 A JP 2009523852A JP 2010501478 A5 JP2010501478 A5 JP 2010501478A5
Authority
JP
Japan
Prior art keywords
hydrogen
compound
compound according
alkyl
con
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009523852A
Other languages
English (en)
Japanese (ja)
Other versions
JP5465006B2 (ja
JP2010501478A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/017754 external-priority patent/WO2008021213A1/en
Publication of JP2010501478A publication Critical patent/JP2010501478A/ja
Publication of JP2010501478A5 publication Critical patent/JP2010501478A5/ja
Application granted granted Critical
Publication of JP5465006B2 publication Critical patent/JP5465006B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009523852A 2006-08-11 2007-08-10 キナーゼおよびｈｓｐ９０の阻害剤として有用な大環状化合物 Expired - Fee Related JP5465006B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83715406P 2006-08-11 2006-08-11
US60/837,154 2006-08-11
US85873106P 2006-11-13 2006-11-13
US60/858,731 2006-11-13
PCT/US2007/017754 WO2008021213A1 (en) 2006-08-11 2007-08-10 Macrocyclic compounds useful as inhibitors of kinases and hsp90

Publications (3)

Publication Number Publication Date
JP2010501478A JP2010501478A (ja) 2010-01-21
JP2010501478A5 true JP2010501478A5 (en:Method) 2011-06-30
JP5465006B2 JP5465006B2 (ja) 2014-04-09

Family

ID=39082315

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009523852A Expired - Fee Related JP5465006B2 (ja) 2006-08-11 2007-08-10 キナーゼおよびｈｓｐ９０の阻害剤として有用な大環状化合物

Country Status (7)

Country Link
US (2) US8067412B2 (en:Method)
EP (1) EP2136799B1 (en:Method)
JP (1) JP5465006B2 (en:Method)
CN (2) CN103539769B (en:Method)
CA (1) CA2696021C (en:Method)
ES (1) ES2651019T3 (en:Method)
WO (1) WO2008021213A1 (en:Method)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
US8212012B2 (en) * 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues having modified sugar moieties
US8067412B2 (en) 2006-08-11 2011-11-29 Universite De Strasbourg Macrocyclic compounds useful as inhibitors of kinases and HSP90
US7960353B2 (en) * 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
EP2231634B1 (en) 2007-12-07 2016-05-11 Eisai R&D Management Co., Ltd. Intermediates in the synthesis of zearalenone macrolide analogs
US20110190237A1 (en) * 2008-01-15 2011-08-04 Nexgenix Pharmaceuticals Macrocyclic Prodrug Compounds Useful as Therapeutics
MX2010007755A (es) 2008-01-15 2010-12-21 Univ Strasbourg Sintesis de lactonas de acido resorcilico utiles como agentes terapeuticos.
WO2010014617A1 (en) * 2008-07-28 2010-02-04 University Of Kansas Heat shock protein 90 inhibitor dosing methods
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
WO2011041593A1 (en) * 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
CA2808866A1 (en) * 2010-08-20 2012-02-23 The Hospital For Sick Children Compositions and methods for treatment of cystic fibrosis and diseases associated with aberrant protein cellular processing
KR20140021520A (ko) * 2010-10-22 2014-02-20 위니베르시떼 드 스트라스부르 Hsp90 관련 질환의 치료에 유용한 포코옥심 컨쥬게이트
WO2013062923A1 (en) * 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp. MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
AU2014293011A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Compositions to improve the therapeutic benefit of bisantrene
WO2016196256A2 (en) * 2015-06-04 2016-12-08 University Of North Carolina At Greensboro Non-aromatic difluoro analogues of resorcylic acid lactones
WO2022089449A1 (zh) * 2020-10-26 2022-05-05 山东大学 一种特异性热休克蛋白90α亚型抑制剂制备及其应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3196019A (en) * 1964-04-06 1965-07-20 Purdue Research Foundation Anabolic and estrogenic compound and process of making
US3239346A (en) * 1965-02-15 1966-03-08 Commercial Solvents Corp Estrogenic compounds and animal growth promoters
FR96016E (fr) * 1966-06-29 1972-05-19 Commercial Solvents Corp Composé utilisable comme supplément alimentaire pour les animaux.
US3453367A (en) * 1966-06-29 1969-07-01 Commercial Solvents Corp Methods for treating inflammation with estrogenic compounds
NL131183C (en:Method) * 1966-12-13
US3758511A (en) * 1967-01-18 1973-09-11 Merck & Co Inc Preparation of d,1-zearalenones
US3551454A (en) * 1967-07-26 1970-12-29 Merck & Co Inc Preparation of optically active (-)-zearalenone and intermediates therefor
US3586701A (en) * 1967-08-24 1971-06-22 Commercial Solvents Corp Norzearalane and its production
US3887583A (en) * 1968-05-15 1975-06-03 Commercial Solvents Corp Products and process
US3591608A (en) * 1968-11-15 1971-07-06 Ayerst Mckenna & Harrison Macrocyclic ketolactones
US3621036A (en) * 1969-02-27 1971-11-16 Merck & Co Inc Derivatives of zearalane
US3704249A (en) * 1969-05-01 1972-11-28 Merck & Co Inc Synthesis of the biologically active diastereoisomer of (-) zearalanol
US3860616A (en) * 1969-05-01 1975-01-14 Merck & Co Inc Synthesis of d,1-zearalanol
BE757083A (fr) * 1970-02-16 1971-03-16 Commercial Solvents Corp Nouveaux produits a activite antibacterienne
BE757082A (fr) * 1970-02-16 1971-03-16 Commercial Solvents Corp Procede de preparation de nouveaux produits a activite antibacterienne
US3687982A (en) * 1971-03-09 1972-08-29 Commercial Solvents Corp Separation of mixed diastereoisomers of zearalanol
US3901922A (en) * 1972-04-25 1975-08-26 Commercial Solvents Corp Synthesis of zearalanone and related compounds and intermediates useful in their synthesis
US3836544A (en) * 1972-04-25 1974-09-17 Commercial Solvents Corp Synthesis of zearalanes ii and related compounds and intermediates useful in the syntheses thereof
US3903115A (en) * 1972-04-25 1975-09-02 Commercial Solvents Corp Synthesis of zearalanes II and related compounds and intermediates useful in the syntheses thereof
US3810918A (en) * 1972-04-25 1974-05-14 Commercial Solvent Corp Synthesis of zearalanone
US3957825A (en) * 1972-04-25 1976-05-18 Commercial Solvents Corporation Process for synthesizing zearalanone and related compounds
US3901921A (en) * 1972-04-25 1975-08-26 Commercial Solvents Corp Synthesis of zearalanes and related compounds and intermediates useful in the syntheses thereof
US3852307A (en) * 1972-04-25 1974-12-03 Commercial Solvents Corp Synthesis of zearalanone and related compounds
US3925423A (en) * 1974-01-22 1975-12-09 Commercial Solvents Corp Resorcyclic acid lactones and their production
US3965275A (en) * 1974-02-11 1976-06-22 Commercial Solvents Corporation Composition and method
US3954805A (en) * 1974-06-06 1976-05-04 Commercial Solvents Corporation Process for preparing zearalene type compounds
US4035504A (en) * 1975-05-12 1977-07-12 Imc Chemical Group, Inc. Method for treating cholesterolemia by administering resorcylic acid lactone derivatives
US4088658A (en) * 1976-11-04 1978-05-09 Imc Chemical Group, Inc. Synthesis of dideoxyzearalane and related compounds
US4042602A (en) * 1976-11-04 1977-08-16 Imc Chemical Group, Inc. Synthesis of dideoxyzearalane and related compounds
US4228079A (en) * 1978-10-30 1980-10-14 W. R. Grace & Co. Dialkoxy monorden derivatives
US4670249A (en) * 1985-04-12 1987-06-02 International Minerals & Chemical Corp. Growth-promoting compositions
EP0248916A1 (en) * 1986-06-05 1987-12-16 C.R.C. Compagnia di Ricerca Chimica S.p.A. Method for separation of 3S,7R-3,4,5,6,7,8,9,10,11,12-decahydro-7,14,16-trihydroxy-3-methyl-1H-2-benzoxacyclotetradecin-1-one from its 3S,7S-diastereomer
US4751239A (en) * 1987-06-29 1988-06-14 International Minerals & Chemical Corp. 6' Carbonate esters of zearalanol and its derivatives
US4778821A (en) * 1987-07-15 1988-10-18 International Minerals & Chemical Corp. Method for controlling helmintic parasites
US4849447A (en) * 1987-10-13 1989-07-18 Pitman-Moore, Inc. Zearalanol derivatives with anabolic activity
US4902711A (en) * 1988-01-19 1990-02-20 Pitman-Moore, Inc. 6' Carbamate esters of zearalanol and its derivatives
US5650430A (en) * 1990-06-06 1997-07-22 Sankyo Company, Limited Radicicol derivatives, their preparation and their anti-tumor activity
IE911915A1 (en) * 1990-06-06 1991-12-18 Sankyo Co Radicicol derivatives, their preparation and their¹anti-tumor activity
JPH06279279A (ja) 1993-03-26 1994-10-04 Tsumura & Co 血管新生阻害剤
JPH06298764A (ja) 1993-04-15 1994-10-25 Kyowa Hakko Kogyo Co Ltd 免疫抑制剤
US5795910A (en) * 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
US5731343A (en) * 1995-02-24 1998-03-24 The Scripps Research Institute Method of use of radicicol for treatment of immunopathological disorders
WO1996033989A1 (en) * 1995-04-26 1996-10-31 Kyowa Hakko Kogyo Co., Ltd. Radicicol derivatives
US5710174A (en) * 1995-06-07 1998-01-20 Zymo Genetics, Inc. Factor XIIIA inhibitor
JPH09202781A (ja) 1996-01-25 1997-08-05 Sankyo Co Ltd ラディシコール誘導体
CN1211244A (zh) * 1996-10-25 1999-03-17 协和发酵工业株式会社 根赤壳菌素衍生物
JPH10265381A (ja) 1997-03-24 1998-10-06 Sankyo Co Ltd 血管再狭窄予防剤
WO1999055689A1 (en) 1998-04-24 1999-11-04 Kyowa Hakko Kogyo Co., Ltd. Radicicol derivatives
JP2002533389A (ja) * 1998-12-24 2002-10-08 ノーベーション ファーマシューティカルズ インコーポレーテッド ｍＲＮＡ安定性に影響する化合物およびそのための使用
JP2000236894A (ja) 1999-02-19 2000-09-05 Kyowa Hakko Kogyo Co Ltd ラディシコールの製造方法
AU2001271567A1 (en) 2000-06-29 2002-01-14 Trustees Of Boston University Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders
US6946456B2 (en) * 2000-07-28 2005-09-20 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
AU2001278152C1 (en) * 2000-08-04 2009-02-05 Board Of Regents, The University Of Texas System Synthetic salicylihalamides, apicularens and derivatives thereof
US6734209B2 (en) * 2001-08-03 2004-05-11 Board Of Regents The University Of Texas System Synthetic salicylihalamides, apicularens and derivatives thereof
ES2354039T3 (es) 2000-08-18 2011-03-09 Millennium Pharmaceuticals, Inc. Derivados de n-aril-{4-[7-(alcoxi)quinazolin-4-il]piperazinil}carboxamida como inhibidores de pdgfr.
DE60120427D1 (de) * 2000-08-25 2006-07-20 Sloan Kettering Inst Cancer Radicicol und monocillin und ihre analogen und ihre anwendungen
CA2426952C (en) * 2000-11-02 2012-06-26 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
JP2004292315A (ja) 2000-12-14 2004-10-21 Chugai Pharmaceut Co Ltd Ｔａｋ１阻害剤
US20030211469A1 (en) * 2001-07-16 2003-11-13 Lloyd Waxman Inhibiting hepatitis c virus processing and replication
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
JP2003113183A (ja) * 2001-10-05 2003-04-18 Kyowa Hakko Kogyo Co Ltd リウマチ治療剤
EP1450784A4 (en) * 2001-11-09 2005-02-09 Conforma Therapeutics Corp HSP90-INHIBITABLE ZEARALANOL COMPOUNDS AND METHOD FOR THEIR PREPARATION AND USE
CA2468202A1 (en) * 2001-12-12 2003-06-19 Conforma Therapeutics Corporation Assays and implements for determining and modulating hsp90 binding activity
GB0202871D0 (en) * 2002-02-07 2002-03-27 Cancer Res Ventures Ltd Assays,methods and means
AU2003224672B2 (en) * 2002-03-08 2010-02-04 Eisai R&D Management Co., Ltd. Macrocyclic compounds useful as pharmaceuticals
CN1652743A (zh) * 2002-04-17 2005-08-10 大正制药株式会社 毛发生长补剂
AU2003264357A1 (en) * 2002-08-29 2004-04-30 Kyowa Hakko Kogyo Co., Ltd. Hsp90 FAMILY PROTEIN INHIBITORS
US20060251574A1 (en) * 2002-12-12 2006-11-09 Adeela Kamal Cytotoxins and diagnostic imaging agents comprising hsp90 ligands
US7959915B2 (en) * 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
US20070004674A1 (en) * 2003-08-22 2007-01-04 Kyowa Hakko Kogyo Co. Ltd. Remedy for diseases associated with immunoglobulin gene translocation
US20080108694A1 (en) * 2003-12-19 2008-05-08 Samuel J Danishefsky Novel Macrocycles and Uses Thereof
WO2005105077A1 (en) * 2004-04-28 2005-11-10 Massachusetts Eye & Ear Infirmary Inflammatory eye disease
JP2008514635A (ja) * 2004-09-27 2008-05-08 コーザン バイオサイエンシス インコーポレイテッド 特異的キナーゼ阻害剤
WO2006119456A2 (en) * 2005-05-04 2006-11-09 University Of Vermont And State Agricultural College Methods and compositions for treating toxoplasma
US8067412B2 (en) 2006-08-11 2011-11-29 Universite De Strasbourg Macrocyclic compounds useful as inhibitors of kinases and HSP90

Similar Documents

Publication Publication Date Title
JP2010501478A5 (en:Method)
JP2008510828A5 (en:Method)
JP2009515988A5 (en:Method)
JP2010504908A5 (en:Method)
JP2006524225A5 (en:Method)
JP2009536620A5 (en:Method)
JP2004516314A5 (en:Method)
EP2397476A3 (en) Indole derivative having PGD2 receptor antagonist activity
JP2010504343A5 (en:Method)
JP2007524696A5 (en:Method)
JP2008525416A5 (en:Method)
JP2008546770A5 (en:Method)
JP2007516205A5 (en:Method)
JP2006505543A5 (en:Method)
JP2018531987A5 (en:Method)
JP2020143129A5 (en:Method)
JP2015526453A5 (en:Method)
JP2005527542A5 (en:Method)
JP2018529690A5 (en:Method)
RU2010117193A (ru) Антималярийные соединения с гибкими боковыми цепями
JP2007500222A5 (en:Method)
JP2005526794A5 (ja) ベンズイミダゾールおよびマイトジェン活性化およびｒｈｏキナーゼ阻害剤としてのその使用
JP2005511594A5 (en:Method)
JP2004523478A5 (en:Method)
JP2017509611A5 (en:Method)